Overview
Frankfurt, December 1, 2022 – McDermott Will & Emery advised Ryvu Therapeutics S.A., a cancer therapeutics clinical development company headquartered in Krakow, Poland, on a research collaboration agreement with Mainz-based biotechnology company BioNTech.
The collaboration aims on the joint development and marketing of immunomodulatory small-molecule active ingredients for cancer therapy. In addition, Ryvu will grant BioNTech exclusive worldwide development and commercialization rights to Ryvu’s STING agonist portfolio.
Under the terms of the agreement, Ryvu will receive an upfront payment of €20 million from BioNTech for certain rights to Ryvu’s STING agonist portfolio and for certain rights and options to license several small molecule drug programs. In addition, BioNTech committed to an equity investment of €20 million.
Ryvu Therapeutics S.A., a stock-listed company headquartered in Krakow, Poland, focuses on drug discovery and development, particularly novel small molecule cancer therapies.
McDermott counsel Monika Richter acted as advisor to Ryvu along with Ryvu general counsel Dawid Radziszewski.
About McDermott
McDermott Will & Emery partners with leaders around the world to fuel missions, knock down barriers and shape markets. Our team works seamlessly across practices and industries to deliver highly effective solutions that propel success. More than 1,200 lawyers strong, we bring our personal passion and legal prowess to bear in every matter for our clients and the people they serve.
